Full-scale rollout of telemedicine operations in China
First written in FY2020-Q3. 16 of 19 entries say "Restated". Latest entry: 2026-08-05.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「We are continuing initiatives to expand the business, including adding functions to the “AI-RAD” artificial intelligence engine platform that assists image diagnosis and preparations to fully launch operations in Asia.」
The company continues to add functions to AI-RAD and prepare for business expansion in Asia. No new milestone marking completion of the overseas expansion is provided. - FY2025RestatedAnnual report
「We are continuing initiatives to expand the business, including adding functions to the “AI-RAD” artificial intelligence engine platform that assists image diagnosis and preparations to fully launch operations in Asia.」
The company continues to add functions to AI-RAD and prepare for business expansion in Asia. No new milestone marking completion of the overseas expansion is provided. - FY2024SoftenedAnnual report
「We are continuing initiatives to expand the business, including adding functions to the “AI-RAD” artificial intelligence engine platform that assists image diagnosis and preparations to fully launch operations in Asia.」
The geographic scope has narrowed in the wording from "business expansion overseas" immediately prior to "business expansion in Asia." - FY2024-Q3RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas.」
The company reiterates that it continues to add functions to AI-RAD and prepare for the full-scale development of its overseas business. No new milestone marking completion of the overseas expansion is provided. - FY2024-Q2RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas.」
The company reiterates that it continues to add functions to AI-RAD and prepare for the full-scale development of its overseas business. No new milestone marking completion of the overseas expansion is provided. - FY2024-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas, including China.」
The company reiterates that it continues to add functions to AI-RAD and prepare for the full-scale development of its business overseas, including China. - FY2023ReframedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas, including China.」
The company has broadened the wording from preparations for expansion into China to expansion overseas, including China. - FY2023-Q3RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The company reiterates that it continues to add functions to AI-RAD and prepare for expansion into China. No new milestone marking completion of the China expansion is provided. - FY2023-Q2RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The company reiterates that it continues to prepare for the full-scale development of its business in China. - FY2023-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The company reiterates that it continues to prepare for the full-scale development of its business in China. No new milestone marking completion of the China expansion is provided. - FY2022RestatedAnnual report
「The company will establish a base in China, where demand for radiology reading is increasing, and promote the rollout of inbound second-opinion services.」
The company reiterates its policy of rolling out inbound second-opinion services using its base in China, but provides no new completed milestone. - FY2022-Q2RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, toward practical application, and preparing for the full-scale development of its business in China.」
The company reiterates that it continues to prepare for the full-scale development of its business in China. No new completed milestone is provided. - FY2022-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The company reiterates that it continues to prepare for the full-scale development of its business in China. No new completed milestone is provided. - FY2021-Q3RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The company reiterates that it continues to prepare for the full-scale development of its business in China. No new completed milestone is provided. - FY2021-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The company states that it continues to prepare for the full-scale development of its business in China, but provides no new completed milestone. - FY2020RestatedAnnual report
「Capitalizing on the advantage that the data are nonverbal and readily transferable across borders, the company will establish a base in China, where demand for radiology reading is increasing, and promote the rollout of inbound second-opinion services.」
The company reaffirms its policy of rolling out second-opinion services using its base in China, but this filing provides no new completed milestone. - FY2020-Q3AdvancedAnnual report
「In April 2019, the company established 医解网（上海）科技有限公司 to accelerate the full-scale development of its business in China.」
The company cites the establishment of a local subsidiary in April 2019 as a specific milestone in its expansion into China.